You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed

Showing 26 - 50 of 7,775
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory B-cell Malignancies Trial (AC676)

Not yet recruiting
  • Relapsed/Refractory B-cell Malignancies
  • (no location specified)
Mar 27, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Light Chain Amyloidosis Trial (FKC288)

Not yet recruiting
  • Light Chain Amyloidosis
  • (no location specified)
Jul 30, 2023

Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

Not yet recruiting
  • Relapsed or Refractory T-cell Lymphomas
  • Sendai-shi, Miyagi, Japan
    Local Institution - 0001
Sep 12, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)

Not yet recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Miami, Florida
    University of Miami
May 31, 2023

Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

Available
  • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Magrolimab
  • (no location specified)
Jan 18, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (Mitoxantrone HCl liposome/Dexamethasone/daratumumab)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
May 4, 2023

Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

Not yet recruiting
  • Relapsed/Refractory AML
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 28, 2023

Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

Not yet recruiting
  • Relapsed/Refractory Aggressive B-Cell Malignancies
  • ONCT-808
  • Bridging Therapy
  • (no location specified)
Jan 19, 2023

Multiple Myeloma Trial (CM313 injection)

Not yet recruiting
  • Multiple Myeloma
  • CM313 injection
  • (no location specified)
Nov 6, 2023

AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)

Recruiting
  • AML
  • MDS
  • Tuebingen, Baden-Wuerttemberg, Germany
    University Hospital
Nov 30, 2023

Multiple Myeloma Trial (AZD0305)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 24, 2023

Adult Patients With Diagnosed Relapsed or Refractory B-cell Lymphoma Who Have Completed Their First Treatment With Regiorense

Recruiting
  • Adult Patients With Diagnosed Relapsed or Refractory B-cell Lymphoma Who Have Completed Their First Treatment With Regiorense Injection
  • Relmacabtagene Autoleucel Injection
  • Shanghai, Shanghai, China
    NO.197， Ruijin Er Road
Mar 28, 2023

Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Plasma Cell Leukemia in Relapse
  • Biological
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital
May 29, 2023

Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

Not yet recruiting
  • Lymphoma, Primary Effusion
  • Daratumumab SC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 23, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

Not yet recruiting
  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
  • (no location specified)
Sep 25, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • B7-H3 target, CAR gene modified gdT cell injection
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital， Zhejiang University School of Med
    Feb 15, 2023

    Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

    Recruiting
    • Peripheral T Cell Lymphoma
    • +2 more
    • Chidamide combined with Duvillisib
    • Xiamen, Fujian, China
      The First Affiliated Hosptial of Xiamen University
    Nov 28, 2023